Session 2: Novel Tools to Improve Understanding of Modulation in Transporter Function in Specific Populations

Co-Chairs: Aleksandra Galetin, University of Manchester, Manchester, UK & Xinning Yang, US FDA, Silver Spring, Maryland, USA

Coproporhyrin I in Different Patient Populations – Implications on DDI Assessment 

Manthena Varma, Pfizer, Groton, Connecticut, USA

Endogenous Biomarkers for Renal Drug Transporters in Patients with Impaired Renal Function 

 Aleksandra Galetin, University of Manchester, Manchester, UK

Selected Abstract Talks

     P1. GADOXETIC ACID-ENHANCED HEPATIC MAGNETIC RESONANCE IMAGING AND CIRCULATING COPROPORPHYRIN I IN THE ASSESSMENT OF DRUG TRANSPORTER ACTIVITY IN NONALCOHOLIC FATTY LIVER DISEASE       Rommel G Tirona, Departments of Physiology & Pharmacology and Medicine, University of Western Ontario, London, Ontario, Canada

     P2. IDENTIFICATION OF ENDOGENOUS SUBSTRATES OF RENAL ORGANIC CATION TRANSPORTERS AS POTENTIAL BIOMARKERS BY UNTARGETED METABOLOMICS ANALYSIS OF CIMETIDINE-TREATED RAT BLOOD AND         URINE SAMPLES
     Anoud Ailbouni,Department of Pharmaceutical Sciences, Washington State University, Spokane, Washington, USA

     P3. DE NOVO IDENTIFICATION AND VALIDATION OF HUMAN ENDOGENOUS BIOMARKERS OF RENAL ORGANIC ANION TRANSPORTERS FOR PREDICTING INTERINDIVIDUAL VARIABILITY
     Aarzoo Thakur, Department of Pharmaceutical Sciences, Washington State University, Spokane, Washington, USA

     P4. PBPK MODELING OF COPROPORPHYRIN I: EVALUATION OF THE IMPACT OF SLCO1B1 GENOTYPE, ETHNICITY AND OATP1B-MEDIATED DDIS
     Yuki Ujihira, Centre for Applied Pharmacokinetic Research, School of Health Sciences, The University of Manchester, UK and Laboratory for Safety Assessment and ADME, Pharmaceuticals Research Center, Asahi             Kasei Pharma Corporation, Shizuoka, Japan

     P5. INVESTIGATING INTRINSIC, EXTRINSIC, AND DISEASE STATE IMPACT ON ENDOGENOUS BIOMARKERS IN RENAL-TRANSPORTER-MEDIATED DRUG DRUG INTERACTIONS
     HeeJae Choi, Boehringer Ingelheim, Ridgefield, Connecticut, USA

     P6. ELUCIDATING ELIMINATION PATHWAYS OF ENDOGENOUS BIOMARKERS FOR ORGANIC ANION TRANSPORTER 1/3 (OAT1/3) INHIBITION IN CYNOMOLGUS MONKEYS 
     Renmeng Liu, Drug Metabolism, Gilead Sciences Inc., Foster City, California, USA

     P7. INCEPTION & DEVELOPMENT OF A LC-MS/MS ASSAY FOR THE MULTIPLEXED QUANTITATION OF NINE HUMAN DRUG TRANSPORTER BIOMARKERS
     Eugene P. Kadar, Bioanalytical Group, Medicine Design, Pfizer Worldwide Research & Development, Pfizer Inc., Groton, Connecticut, USA

Drug Transporters in Pediatrics: Ontogeny, Variability, and Clinical Significance 

Bhagwat Prasad, Washington State University, Spokane, Washington, USA

Roundtable Discussion with Speakers